Epredia bringt Laser-Kassettendrucker auf den Markt, die die Probenverfolgung und die Effizienz des Labors verbessern

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523),  and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScanTM, a product under development as a medical device designed to support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, to support distribution of this new device to surgeons after it is on the market.

Skin cancer is the most common group of cancers diagnosed worldwide , and it is estimated that one in five Americans will develop skin cancer in their lifetime . Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year . Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer. 

MarginScan™ is being designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is being designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.

With this agreement, Epredia plans to serve as the primary distribution partner of MarginScan™ and have exclusive distribution rights in the United States. Along with distribution, Epredia plans to be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. After product launch, Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.

Under these planned arrangements, after launch, MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia also has plans to provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions. 

The two companies anticipate a 2025 U.S. launch for MarginScan™. The planned distribution agreement builds on a previous agreement between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.  

Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”

Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be making plans with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We will be proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products in the future. We believe that MarginScan™ will play an important role in skin cancer detection and treatment”

Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner for this planned initiative to bring this breakthrough device to our network of providers and their patients when it is launched.”

---

Über Epredia

Epredia ist ein weltweit führendes Unternehmen im Bereich der anatomischen Pathologie und bietet umfassende Lösungen für die Präzisionskrebsdiagnostik und Gewebediagnostik. Zu den wichtigsten Marken von Epredia gehören Erie Scientific, Menzel-Gläser, Microm, Shandon und Richard-Allan Scientific. Das Portfolio von Epredia umfasst Objektträger, Instrumente und Verbrauchsmaterialien. Epredia wurde nach der Übernahme des Geschäftsbereichs Anatomische Pathologie von Thermo Fisher Scientific durch PHC Holdings im Jahr 2019 gegründet. Epredia verfügt über große Standorte in den USA, Großbritannien, Deutschland, der Schweiz und China und beschäftigt insgesamt rund 1.200 Mitarbeiter. Epredia hat es sich zur Aufgabe gemacht, durch die Verbesserung der Krebsdiagnostik für Patienten auf der ganzen Welt Leben zu verbessern. Weitere Informationen über Epredia und seine Produkte finden Sie unter www.epredia.com.

Über die PHC Holdings Corporation (PHC-Gruppe)

Die PHC Holdings Corporation (TSE 6523) ist ein weltweit tätiges Gesundheitsunternehmen, das sich zum Ziel gesetzt hat, zur Gesundheit der Gesellschaft durch Gesundheitslösungen beizutragen, die einen positiven Einfluss haben und das Leben der Menschen verbessern. Zu seinen Tochtergesellschaften (zusammen als PHC-Gruppe bezeichnet) gehören PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford und Wemex. Gemeinsam entwickeln, produzieren, verkaufen und betreuen diese Unternehmen Lösungen in den Bereichen Diabetesmanagement, Gesundheitswesen, Biowissenschaften und Diagnostik. Der konsolidierte Nettoumsatz der PHC-Gruppe belief sich im Geschäftsjahr 2012 auf 356,4 Milliarden JPY, wobei die Produkte und Dienstleistungen in mehr als 125 Ländern vertrieben werden.
www.phchd.com

Für weitere Informationen wenden Sie sich bitte an:

Julia Cottrill
PHC Group Corporate Communications
Email: julia.cottrill@phchd.com